<DOC>
	<DOCNO>NCT00008242</DOCNO>
	<brief_summary>RATIONALE : Thalidomide may stop growth multiple myeloma stop blood flow cancer cell . Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining thalidomide chemotherapy may kill cancer cell . PURPOSE : Phase II trial study effectiveness thalidomide , doxorubicin , dexamethasone treat patient untreated stage II stage III multiple myeloma .</brief_summary>
	<brief_title>Thalidomide , Doxorubicin , Dexamethasone Treating Patients With Untreated Stage II Stage III Multiple Myeloma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine response rate patient previously untreated stage II III multiple myeloma treat thalidomide , doxorubicin , dexamethasone . II . Determine safety toxicity regimen patient population . OUTLINE : Patients receive oral dexamethasone day 1-4 , 9-12 , 17-20 , doxorubicin IV day 1 , oral thalidomide daily . Treatment repeat every 30 day 4 course absence unacceptable toxicity disease progression . PROJECTED ACCRUAL : A total 21-45 patient accrue study within approximately 1 year .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm multiple myeloma Stage II disease Symptomatic due progressive disease OR Stage III disease No stage I multiple myeloma smolder myeloma PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 03 Life expectancy : More 4 month Hematopoietic : Absolute granulocyte count least 1,500/mm3* Platelet count least 100,000/mm3* *Unless due multiple myeloma Hepatic : Bilirubin great 2.0 mg/dL ALT AST great 3 time upper limit normal ( ULN ) Alkaline phosphatase great 3 time ULN Renal : Elevated creatinine allow Cardiovascular : LVEF least 50 % MUGA ECHO No active angina No myocardial infarction within past 6 month Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception least 4 week prior , , least 4 week study No grade II great preexist neuropathy No concurrent prior active malignancy within past 2 year except adequately treat nonmelanoma skin cancer carcinoma situ cervix Prior T1a T1b prostate cancer ( detect incidentally transurethral resection prostate ( TURP ) comprise less 5 % resected tissue ) allow PSA normal since TURP HIV negative No AIDSrelated illness No medical condition would preclude study PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy multiple myeloma Endocrine therapy : No 1 course prior pulse dexamethasone Prior steroid less 1 month duration emergent indication lifethreatening lesion ( e.g. , hypercalcemia spinal cord compromise ) allow Radiotherapy : Prior radiotherapy allow Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
</DOC>